|
|
 | | | |
- close
- close
- close
- close
Arrowhead Research (ARWR) |
QUOTE AND NEWS
Business Wire
May 9
Comment
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that David Lewis, Ph.D., Vice President Biology and Site Head of its Madison, WI research and development facility presented data at the European Foundation for Clinical Medicine Conference
StreetInsider.com
May 8
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Arrowhead+Research+Corp.+%28ARWR%29+Widens+Q1+Loss+to+50cShare/7416017.html for the full story.
Business Wire
May 8
Comment
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced financial results for its fiscal 2012 second quarter ended March 31, 2012. Fiscal 2012 Second Quarter and
Business Wire
May 3
Comment
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that senior management will present data for its Dynamic PolyConjugate™ (DPC) delivery platform for siRNA delivery including its RNAi therapeutic candidate for the treatment of hepatitis
Business Wire
May 1
Comment
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 second quarter ended March 31, 2012, on Tuesday, May 8, 2012 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate
Business Wire
Apr 11
Comment
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced that it has acquired Alvos Therapeutics, Inc. (formerly known as Mercator Therapeutics, Inc.), a
Business Wire
Mar 7
Comment
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that it has released a white paper describing the health problem posed by the hepatitis B virus (HBV),
Business Wire
Mar 5
Comment
Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide
Business Wire
Feb 29
Comment
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. US 8,114,983 B2
Benzinga
Jan 4
Comment
Arrowhead Research Corporation (NASDAQ: ARWR), today announced that the
Investigational New Drug Application for its first obesity drug
candidate, Adipotide^, was accepted by the U.S. Food and Drug Administration
allowing the initiation of a...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
